**Appendix C Reporting proforma for vulval cancer resection specimens**

Surname ............................... Forenames ........................... Date of birth .............................

Hospital ................................ Hospital no ........................... NHS/CHI no ............................

Date of receipt ...................... Date of report ....................... Report no ...............................

Pathologist ............................ Surgeon ...............................

**Clinical**

*Procedure*‡*:*

Local excision  Left wide local excision  Right wide local excision

Partial vulvectomy: Left  Right  Anterior  Posterior 

Total vulvectomy 

*Lymph nodes:*  Present  Absent 

*If present, tick all received:*

|  |  |  |
| --- | --- | --- |
|  | Left | Right |
| Sentinel nodes |  |  |
| Inguinofemoral nodes |  |  |
| Pelvic nodes |  |  |
| Other, specify ………………. |  |

**Macroscopy**

*Specimen size:* ….. x …… x …… (L x W x thickness in mm)

*Tumour site (tick all that apply)* ‡*:*

Labium majus: Left  Right 

Labium minus: Left  Right 

Central  Clitoral  Cannot be determined 

OR

No visible tumour

*Maximum macroscopic tumour dimension (if visible)*‡*:* …… mm

*Nearest macroscopic margin (specify)*: ………

*Nearest macroscopic margin distance* ……… mm

**Microscopy**

*Histological type*‡*:*

|  |  |
| --- | --- |
| Squamous tumours Squamous cell carcinoma, NOS Keratinising SCC  Non-keratinising SCC  Basaloid SCC  Warty SCC  Verrucous SCC  Basal cell carcinoma  | Glandular tumours Bartholin gland carcinomas Adenocarcinoma  Adenoid cystic carcinoma  Adenosquamous carcinoma  Transitional cell carcinoma Adenocarcinoma of mammary gland type  Adenocarcinoma of Skene gland origin  Adenocarcinoma of sweat gland type  Adenocarcinoma of intestinal type  |
| Neuroendocrine tumours Small cell neuroendocrine carcinoma  Large cell neuroendocrine carcinoma  Merkel cell carcinoma Carcinoma, type cannot be determined  Other (specify): .... |

*Differentiation*‡*:*

Well (grade 1) Moderate (grade 2)  Poor (grade 3)

Undifferentiated (grade 4) Not applicable

Tumour size:

*Maximum horizontal dimension*‡*:* ……… mm

*Depth of invasion*‡: …….. mm

AND/OR

*Tumour thickness*‡: …….. mm

*Lymphovascular invasion*‡*:* Present  Not identified  Uncertain 

*Perineurial (intraneural) invasion:* Present  Not identified  Uncertain 

Margins:

*Extension to margin*‡: No . Yes 

 If yes specify:

Left  Right 

Anterior  Posterior 

Deep Unorientated 

Other (specify) …….

 *If margins are not involved, which is the closest margin?*

Left  Right 

Anterior  Posterior 

Deep Unorientated 

Other (specify) ……..

*What is the distance of the tumour to the closest margin*: …. mm

*High-grade VIN/HSIL (VIN2/3)*: Present  Not identified  Uncertain 

 If present:

Excised  Not excised 

 If not excised, *which margins are involved?*:

Left  Right 

Anterior  Posterior 

Other (specify): …….

*Differentiated VIN*: Present  Not identified  Uncertain 

 If present:

Excised  Not excised 

 If not excised, *which margins are involved?*:

Left  Right 

Anterior  Posterior 

Other (specify): …….

*Paget disease*: Present  Not identified  Uncertain 

 If present:

Excised  Not excised 

 If not excised, *which margins are involved?*:

Left  Right 

Anterior  Posterior 

Other (specify): …….

*Non-neoplastic epithelial disease:*

Lichen sclerosus  Lichen planus  Squamous hyperplasia 

Lymph nodes, if received‡:

|  |  |  |
| --- | --- | --- |
|  | Left | Right |
|  | Number positive  | Number received | Number positive | Number received |
| Sentinel lymph nodes |  |  |  |  |
| Inguinofemoral lymph nodes |  |  |  |  |
| Pelvic lymph nodes |  |  |  |  |
| Other, specify ………………. |  |  |  |  |

Size of sentinel lymph node deposit(s) in mm: ………

*Largest lymph node deposit in mm: ……..*

*Extranodal extension*‡ Yes  No 

*Histological evidence of distant metastasis*‡: Present  Not identified 

*Markers for high-risk HPV infection:*

HPV ISH Positive  Negative  Not performed 

p16 immunohistochemistry Positive  Negative  Not performed 

**Staging**

*Provisional FIGO stage (may change following MDT discussion)*: …………………….

*TNM*‡ T... N... M... UICC TNM edition ……

*SNOMED codes*‡*:* ………………………………………………….

Reporting pathologist ……….. Date……./..…../..…..

‡Data items that are currently part of the Cancer Outcomes and Services Dataset (COSD) version 7.